The American Society of Clinical Oncology recently released some good stats. If you are a newly diagnosed myeloma patient taking Revlimid and low-dose dex, your chances of surviving the next two years are 93 percent. (There aren't any stats beyond two years yet, because Revlimid is so new). If you're a totally healthy person who doesn't have myeloma, your chances of surviving the next two years are 96 percent.
This means you only have to worry about me three percent more than you'd worry about a regular person.